Condition: Type2 Diabetes · Heart Failure With Preserved Ejection Fraction · Sponsor: The University of Texas Health Science Center at San Antonio
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
This description comes directly from the study's public registry record.
Carolina Solis-Herrera, MD · 210-567-4900 · solisherrera@uthscsa.edu
Francisca M Acosta, PhD · 210-450-8677 · acostafm@uthscsa.edu
Always discuss trial participation with your own doctor first.
| University of Texas Health Science Center at San Antonio | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05057806